Treating Blood Cancers

Shira Dinner, MD — **The Role of the Healthcare Team in Biomarker Testing** Oct 25, 2024
Jennifer R. Rushton, MD, Clinical Pathology Associates and the Baptist Health System, San Antonio, TX and Eric Severson, MD, PhD, Labcorp Oncology, Shelton, CT
Recorded on July 2, 2024

Join us, as we dive into the crucial topic of biomarker testing with Dr. Jennifer Rushton from Clinical Pathology Associates and the Baptist Health System, and Dr. Eric Severson from Labcorp Oncology. They explore the role of the healthcare team in integrating biomarker testing into clinical practice and decision-making, as well as strategies for effective patient communication about its importance and implications. They also share their perspectives on the future of biomarker testing. Tune in today to learn more!
**Jennifer R. Rushton, MD**
Clinical Pathology Associates
Medical Director, Pathology and Laboratory Medicine
Baptist Health System
San Antonio, TX **Eric Severson, MD, PhD**
Executive Director Medical Affairs and Evidence Generation
Labcorp Oncology
Shelton, CT Feedback
*This episode is supported by Labcorp Oncology.*

Krish Patel, MD — **Treating Hodgkin Lymphoma: What HCPs Need to Know** Sep 27, 2024
Alex F. Herrera, MD, City of Hope Medical Center, Duarte, CA

Recorded on June 27, 2024

**Alex F. Herrera, MD**
Associate Professor
Chief, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation
Associate Medical Director, Briskin Center for Clinical Research & City of Hope
Duarte Clinical Trials Office
City of Hope Medical Center
Duarte, CA
In this episode, Dr. Alex Herrera from City of Hope explores the intricacies of Hodgkin lymphoma, from diagnosis and monitoring techniques to treatment goals and options. He discusses emerging therapies, including the significance of clinical trials, strategies for managing side effects, long-term effects of treatment, and resources for healthcare professionals, patients, and families. Tune in to learn more today! **Feedback**

**Clinical Perspectives on Hereditary Myeloid and Hematologic Disorders** Aug 29, 2024
Ximena Jordan-Bruno, MD, University of Pennsylvania, Philadelphia, PA

Recorded on June 4, 2024

**Ximena Jordan-Bruno, MD**
Assistant Professor, Division of Hematology/Oncology
University of Pennsylvania
Philadelphia, PA
Join us for this fascinating episode, where Dr. Ximena Jordan-Bruno from the University of Pennsylvania explores hereditary myeloid and hematologic disorders, covering their classifications, mutations, and related germline predisposition syndromes. Learn about key clinical features, diagnostic approaches, the role of genetic counseling, and future research directions. Tune in today for valuable updates to enhance your understanding and practice! **Feedback**

**Navigating Adult Survivorship Care** Aug 16, 2024
Susan Hong, MD, Virginia Commonwealth University, Richmond, VA

Recorded on May 21, 2024

**Susan Hong, MD**
Director, Cancer Survivorship Program, Massey Comprehensive Cancer Center
Associate Professor, School of Medicine Internal Medicine
Virginia Commonwealth University
Richmond, VA Tune in as Dr. Susan Hong, Cancer Survivorship Program Director at Virginia Commonwealth University’s Massey Cancer Center, discusses survivorship care in adults. She explores the intersection of healthcare professional and patient goals in survivorship care, as well as disparities and challenges impacting access and follow-up. Dr. Hong offers strategies to improve adherence to survivorship care and communication between survivors and primary care practitioners. She also shares educational resources for healthcare professionals, patients, and caregivers to support effective survivorship care. Listen to this informative episode today! **Feedback**
*This episode is supported by Genentech, Inc. & Biogen and Merck & Co., Inc.*

**Managing Oral and Dental Complications in Cancer Treatment** Jul 11, 2024
David Dean, DDS, MSD, DABOM, FDS RCSEd, Fred Hutchinson Cancer Center and University of Washington School of Dentistry, Seattle, WA

Recorded on April 25, 2024

**David Dean, DDS, MSD, DABOM, FDS RCSEd**
Director, Oral Medicine
Fred Hutchinson Cancer Center
Clinical Associate Professor
University of Washington School of Dentistry
Seattle, WA Join us, as Dr. David Dean from Fred Hutchinson Cancer Center and the University of Washington School of Dentistry uncovers essential aspects of oral health in cancer care, including symptoms that may indicate a blood cancer, common dental complications that arise from treatment, and insights into preventative care. Dr. Dean also addresses special considerations for patients with cancer needing dental care and strategies for healthcare providers to provide optimal support for patients navigating dental challenges. Tune in to learn more today!

**Exploring Survivorship Needs of Older Adults** Jul 08, 2024
Cesar Rodriguez, MD, Mount Sinai Hospital, New York, NY

Recorded on April 16, 2024

**Cesar Rodriguez, MD**
Associate Professor of Medicine, Tisch Cancer Institute
Clinical Director, Multiple Myeloma Center of Excellence
Mount Sinai Hospital
New York, NY Join us for an insightful episode with Dr. Cesar Rodriguez from Mount Sinai Hospital as he discusses the healthcare provider’s role in survivorship care for older adults. Dr. Rodriguez explores the unique challenges of managing long-term and late effects of treatment and coordinating follow-up care. He also shares valuable perspectives on the impact of language and cultural considerations, along with the importance of caregiver support for older adult survivors. Listen in today!
*This episode is supported by Genentech, Inc. & Biogen and Merck & Co., Inc.*

Insights and Updates on Navigating the AML Landscape Jun 07, 2024

Hagop M. Kantarjian, M.D., MD Anderson Cancer Center, Houston, TX Recorded on March 28, 2024 Hagop M. Kantarjian, M.D. Professor and Chairman, Department of Leukemia Samsung Distinguished University Chair in Cancer Medicine MD Anderson Cancer Center, University of Texas Houston, TX Join us for this episode as Dr. Hagop Kantarjian from MD Anderson Cancer Center discusses the latest advancements and progress in treating Acute Myeloid Leukemia (AML). From understanding genetic mutations to exploring emerging treatment options, Dr. Kantarjian shares valuable insights into the forefront of AML research and care. Learn more today!

CAR T-cell Therapy in 2024 Apr 12, 2024

Michael Tees, MD, MPH, Colorado Blood Cancer Institute, Denver, CO Recorded on March 12, 2024 Michael Tees, MD, MPH Director, Lymphoma Program Lymphoma Executive Committee Member, Sarah Cannon Research Institute Associate Member, Colorado Blood Cancer Institute Denver, CO Join Dr. Michael Tees from the Colorado Blood Cancer Institute, as he discusses Chimeric antigen receptor (CAR) T-cell therapy in 2024. Dr. Tees provides an overview of immunotherapy and approved indications, how to discuss treatment options with your patients, what to consider when referring patients for CAR T-cell therapy, how to prepare patients, and educating patients and caregivers about toxicity management. He also provides insight into the limitations of CAR-T therapy, as well as future directions. Tune in to this informative episode today to learn more! This episode is supported by Bristol Myers Squibb, Johnson & Johnson|Legend Biotech, Kite, a Gilead Company, and Novartis Pharmaceuticals Corporation.

Supporting Healthcare Professionals to Reduce Burnout Mar 14, 2024

Alfred Lee, MD, PhD, Yale University, New Haven, CT Recorded on February 22, 2024 Alfred Lee, MD, PhD Professor of Medicine, Yale School of Medicine Program Director, Hematology and Medical Oncology Fellowship Chief, Division of Classical Hematology, Yale Cancer Center Yale University New Haven, CT Join us for this important and engaging episode, as Dr. Alfred Lee from Yale University addresses stress and burnout in healthcare professionals. While reflecting on his personal experience, Dr. Lee discusses warning signs, symptoms, risk factors, and strategies and resources to help reduce and prevent burnout. Tune in today!

Creating a Roadmap for Adult Survivorship Care Jan 30, 2024

Meghna Ailawadhi, M.B.B.S., M.D., Mayo Clinic, Jacksonville, FL Recorded on December 7, 2023 Meghna Ailawadhi, M.B.B.S., M.D. Cancer Survivorship Consultant, Assistant Professor of Medicine Department of Hematology/Oncology Mayo Clinic Jacksonville, FL In this episode, Dr. Meghna Ailawadhi from the Mayo Clinic in Jacksonville, FL joins us for a conversation on survivorship care for adults. Dr. Ailawadhi discusses the importance of shared decision-making and coordination with primary care, including strategies to support adherence. She also provides an overview of disparities and challenges in survivorship care, as well as education and support resources for healthcare professionals and survivors. Learn more by listening today! This episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Merck & Co. Inc.

Highlights from attending the 2023 ASH Annual Meeting Jan 10, 2024

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 19, 2023 Lee Greenberger, PhD Chief Scientific Officer and SVP The Leukemia & Lymphoma Society Rye Brook, NY Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to discuss highlights from the 65th American Society of Hematology (ASH) Annual Meeting in December 2023, including updates on blood cancer research, treatment, and clinical trials in leukemia, lymphoma, myeloma, MDS, and MPNs. Tune in to this informative update today!

A Conversation on Transplantation Dec 20, 2023

Jeffery Auletta, MD, National Marrow Donor Program® (NMDP)/Be the Match® Recorded on November 30, 2023 Join us as Dr. Jeffery Auletta from the National Marrow Donor Program® (NMDP)/Be the Match® reflects on the history, advances, and future of transplantation to treat blood cancers. Dr. Auletta also shares insights on disparities and barriers to receiving a transplant, expanding access, and how healthcare professionals can support patients through transplantation. Tune in to this engaging episode today!

Addressing Barriers & Disparities for Hispanic/Latinx Blood Cancer Survivors Throughout the Care Journey Dec 13, 2023

Jacqueline Barrientos, MD, MS, Laura Ortiz-Ravick, MA, Kristina Lopez, LCSW Recorded on November 3, 2023 Join us for this special episode, recorded live from the Florida Society of Clinical Oncology Annual Disparities in Cancer Care Summit. Guest host, Kristina Lopez, LCSW and Information Specialist at The Leukemia & Lymphoma Society, speaks with Dr. Jacqueline Barrientos from Mount Sinai Medical Center, and Laura Ortiz-Ravick, Director of Outreach and Health Promotion at The Leukemia & Lymphoma Society about barriers and disparities within the Hispanic and Latinx communities when navigating the cancer journey. Learn more by tuning in here!

Survivorship Care of Older Adults: Addressing the Unique Needs Nov 21, 2023

Frank Penedo, Ph.D, University of Miami, Miami, FL Recorded on August 10, 2023 Tune in as we’re joined by Dr. Frank Penedo from the University of Miami for an important discussion on considerations in survivorship care of older adults. Dr. Penedo outlines long-term and late effects of treatment, including psychosocial implications, and the impact of culture and language on survivorship. He also shares strategies for follow-up care coordination, as well as communicating with survivors and their families. Be part of the conversation today! This episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Merck & Co. Inc.

Measuring Quality of Life in Adolescent and Young Adult Cancer Care Nov 01, 2023

John Salsman, Ph.D, Wake Forest University School of Medicine, Winston-Salem, NC Recorded on June 22, 2023 In this episode, Dr. John Salsman from Wake Forest University School of Medicine joins special staff correspondent, Elissa Baldwin, to discuss quality of life in the cancer experience of adolescents and young adults (AYAs), including unique issues that AYAs face. Dr. Salsman offers approaches to questions healthcare providers can ask when communicating with AYAs and clinical resources for physicians and survivors. Tune in today!

Supporting Adolescent and Young Adult (AYA) Survivors Aug 31, 2023

Tung Wynn, MD, University of Florida, Gainesville, FL and Braulio Hernandez Recorded on June 10, 2023 Join Dr. Tung Wynn from the University of Florida, and Braulio Hernandez, a childhood cancer advocate and AYA survivor of Hodgkin Lymphoma, as they discuss the unique experiences of adolescents and young adults from active treatment to survivorship. Dr. Wynn and Braulio reflect on the physical and psychosocial long-term and late effects of treatment, strategies to support survivors and their families, survivorship guidelines, follow-up care coordination, and resources for clinical staff and for survivors. Listen to this engaging conversation today! This episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Merck & Co. Inc.

Understanding and Treating LGBTQI+ Patients with Cancer Jun 02, 2023

Chasity Burrows Walters, PhD, RN, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on April 13, 2023 In this important conversation, Dr. Chasity Burrows Walters from Memorial Sloan Kettering Cancer Center discusses the barriers that persons within the LGBTQI+ community experience in accessing healthcare and the impact of discrimination on health outcomes. Dr. Burrows Walters offers guidance to help healthcare providers foster a respectful and sensitive environment for patients and their caregivers, including use of pronouns, gender-inclusive language, cancer screening guidelines, and resources for clinical staff and for patients. Learn more by tuning in today!

Chronic Myeloid Leukemia: What HCPs Need to Know Feb 21, 2023

Ehab Atallah, MD, Medical College of Wisconsin, Milwaukee, WI Recorded on January 24, 2023 In this episode, Dr. Ken Miller sits down with Dr. Ehab Atallah, from the Medical College of Wisconsin, to discuss chronic myeloid leukemia (CML) including the development of tyrosine kinase inhibitors (TKIs), challenges with adherence to treatment, side effect management, and long-term and late effects, including cardiac toxicities. Dr. Atallah describes the work of the H. Jean Khoury Cure CML Consortium, shares his insights in to transitioning patients off TKIs, experience with his patients living with measurable residual disease, and excitement about the future of CML therapy. Learn more by tuning in today!

2022 ASH Annual Meeting: Highlights from the Perspective of a Conference Attendee Jan 20, 2023

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 19, 2022 In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to provide an update on the information presented at the 64th American Society of Hematology (ASH) Annual Meeting, including leukemia, lymphoma, myeloma, MDS, and MPNs. Dr. Greenberger discusses updates in blood cancer therapies, including CAR T-cell therapy, bi-specific antibodies, and vaccine therapy, reviews the latest data on COVID-19, and addresses challenges that exist in diversity and equity in the healthcare system, including ways to overcome these barriers. Tune in today!

Understanding Waldenström Macroglobulinemia Jan 04, 2023

Shayna Sarosiek, MD, Dana Farber Cancer Institute, Boston, MA Recorded on December 6, 2022 Waldenström Macroglobulinemia (WM) is a rare blood cell cancer characterized by an excess number of abnormal white blood cells in the bone marrow. How does WM fit into the spectrum of other blood cancer diseases? Who is at risk? What are the genetic factors? Dr. Shayna Sarosiek, from the Dana-Farber Cancer Institute, joins us to provide a deep dive into WM, including testing, monitoring, treatment updates, clinical trials, and so much more. Tune in today! This activity is developed through a collaboration with the International Waldenström’s Macroglobulinemia Foundation.

CAR T-cell Therapy in Review 2022: Updates in Treatment Dec 21, 2022

Sattva S. Neelapu, MD, M.D. Anderson Cancer Center, Houston, TX Recorded on December 16, 2022 Chimeric antigen receptor (CAR) T-cell therapy has generated impressive results in hematologic malignancies, with many drugs still in clinical trials. In this episode, Dr. Sattva S. Neelapu from MD Anderson Cancer Center, joins us to discuss updates on CAR T-cell therapy from the 2022 American Society of Hematology (ASH) Annual Meeting. Dr. Neelapu also provides a high-level overview of how CAR T-cell therapy works, including the manufacturing process, and discusses the risk of recurrence following therapy, risk for patients in the era of COVID-19, secondary cancers, associated costs, roadblocks to therapy, and why early referral matters. Tune in to this informative podcast episode to learn more! This podcast episode is supported by Allogene Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Janssen Oncology & Legend Biotech, Kite, A Gilead Company and Novartis Oncology.

Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia: Part II Nov 16, 2022

Daphne Friedman, MD, Durham VA Health Care System, Durham, NC Recorded on October 20, 2022 In Part II of Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia, Dr. Daphne Friedman, from the Durham VA Health Care System in North Carolina, discusses the importance of a relationship between the provider and the patient when it comes to shared decision making (SDM), including the unique conversations of SDM with young adults and with healthcare providers who are patients. Dr. Friedman also shares challenges with seeking a second opinion, relying on information found on the internet, and additional resources. Tune in today to learn more! This podcast episode is supported by AbbVie Inc. and Genentech, Inc.

AML: Insights, Updates, and Takeaways Oct 27, 2022

Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 7, 2022 Dr. Eytan Stein, from Memorial Sloan Kettering Cancer Center, joins us to reflect on breakthroughs in acute myeloid leukemia, including updates in treatment, long-term and late effects of therapy, and side effect management. Tune in to this episode as Dr. Stein discusses an overview of data presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) as well as updates from The Leukemia & Lymphoma Society’s BEAT AML® Master Trial.

Insights from Attending the 2022 Society of Hematologic Oncology (SOHO) Annual Meeting Oct 14, 2022

Saad Z. Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on September 30, 2022 Join us for this special episode, recorded live from the Tenth Annual Meeting of the Society of Hematologic Oncology in Houston, TX! Guest host and conference attendee, Lauren Berger, Senior Director of Professional Education and Engagement at The Leukemia & Lymphoma Society, speaks with Dr. Saad Usmani, from Memorial Sloan Kettering Cancer Center, about his insights into the progress in immunotherapies in blood cancers shared at the conference. Not able to attend SOHO? Learn more about what was shared at the conference by tuning in here!

What’s New in the Treatment of BPDCN? Sep 20, 2022

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX Recorded on September 6, 2022 Join us as Dr. Naveen Pemmaraju from MD Anderson Cancer Center, returns to discuss blastic plasmacytoid dendritic cell neoplasms (BPDCN)! In this episode, Dr. Pemmaraju provides an overview of BPDCN, including major updates in the treatment of the disease since our last episode on this topic in 2019. What is BPDCN? How is it treated? Is it curable? What resources are available for patients living with this rare disease? Join the conversation and learn more today! This podcast episode is supported by Stemline Therapeutics, Inc.

Mastocytosis: Insight into a Rare Blood Cancer Aug 11, 2022

Jason Gotlib, MD, Stanford University School of Medicine, Palo Alto, CA Recorded on July 19, 2022 Mastocytosis is a rare and complex disease. In this special episode, Dr. Jason Gotlib from the Stanford University School of Medicine in Palo Alto, CA, discusses an overview of the disease, including its subtypes, clinical presentations, and treatment related toxicities. Dr. Gotlib addresses the importance of second opinions, collaborating with multidisciplinary specialists to treat patients, unmet needs and exciting new and emerging treatments. Learn more about the future of mastocytosis by listening to this episode today! This podcast episode is supported by Blueprint Medicines Corporation.

The Role of Genomics in Treating Blood Cancers Jul 20, 2022

Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ Recorded on June 30, 2022 In this episode, Dr. Rafael Fonseca, from the Mayo Clinic in Arizona, joins Dr. Ken Miller to breakdown the complex and complicated nature of genomics and molecular profiling. He discusses the role of molecular profiling in treating blood cancers, explains how we integrate genomics into the standard of care for people living with cancer, the potential of false negatives, provides examples of clinical applications, financial implications, and resources for patients. Tune in to the conversation today! This podcast episode is supported by Blueprint Medicines Corporation.

Insights into Pediatric Survivorship for the HCP Jun 23, 2022

Kevin C. Oeffinger, MD, FASCO, Duke University Medical Center, Durham, NC Recorded on June 9, 2022 Children diagnosed with cancer are a heterogenous population experiencing different cancer diagnoses and therapies. Each journey presents its own physical, emotional, and psychosocial challenges that healthcare providers need to be attentive to. In this episode, Dr. Kevin Oeffinger, from Duke University in Durham, North Carolina, joins us to discuss the history of pediatric survivorship, physical, long-term, and late effects of treatment, including fertility considerations, strategies to support the survivor through psychosocial and cognitive effects, following a survivorship care plan, symptom monitoring, follow-up care, and so much more. Tune in to this important conversation today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Pharmacyclics LLC, An AbbVie Company and Janssen Biotech, Inc.

PedAL: First-of-Its-Kind Global Master Clinical Trial for Pediatric Acute Leukemia Jun 09, 2022

Gwen L. Nichols, MD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on May 20, 2022 Through the LLS Children’s Initiative, The Leukemia & Lymphoma Society (LLS) is setting out to fundamentally change how children with blood cancer are treated and cared for. For children and their families, LLS provides free education, support services, financial assistance, advocacy efforts, and has increased its research investments in childhood blood cancer. As part of this initiative, LLS PedAL, a first-of-its-kind global master clinical trial for pediatric acute leukemia patients, will fundamentally change how children are treated. In this episode, Dr. Gwen Nichols, EVP and Chief Medical Officer joins us to discuss PedAL, including sharing reflections on lack of pediatric ALL and AML therapies that led to the development of this master clinical trial. Dr. Nichols discusses challenges in creating pediatric therapies, the importance of data collection and creating a standard of care, and the ultimate impact PedAL will have on all clinical trials moving forward. Tune in today!

The Role of the Primary Care Physician in Treating Chronic Blood Cancers: Focus on Myeloma May 24, 2022

Zalman Suldan, MD, PhD, Hackensack University Medical Center – Hackensack Meridian Health, Hackensack, NJ Recorded on May 3, 2022 The primary care physician plays an important role in the treatment of patients living with a chronic blood disorder, from early diagnosis to appropriate referral to a hematologist-oncologist, from coordination of care to goals of therapy. In this episode, we are joined by Dr. Zalman Suldan, from Hackensack Medical Center in New Jersey, who shares his unique insights as both a primary care physician and nephrologist. Tune in today! This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.

CAR T-cell Therapy in 2022: What You Need to Know Part II Apr 26, 2022

Rayne H. Rouce, MD, BS, Texas Children’s Cancer Center for Cell and Gene Therapy, Houston, TX Recorded on April 8, 2022 As CAR T-cell therapy continues to evolve in new and exciting ways, new indications are approved and treatment toxicities reduced. In this episode, Dr. Rayne Rouce, from the Texas Children’s Cancer Center for Cell and Gene Therapy at Baylor College in Houston, joins us to discuss hot topics in CAR T-cell therapy, including how CAR-T has evolved over the past few years, understanding why some patients do better than others, access to treatment and overcoming logistics, shared care models with the referring physician, CAR-T in pediatric patients, communicating with patients, and so much more! This podcast episode is supported by Bristol Myers Squibb, CRISPR Therapeutics, Inc., Kite, a Gilead Company, Janssen Oncology & Legend Biotech, and Novartis Pharmaceuticals Corporation.

Everything You Need to Know About Cutaneous T-cell Lymphoma Apr 14, 2022

Francine Foss, MD and John A. Zic, MD, MMHC Recorded on March 28, 2022 This informative episode covers everything you need to know about cutaneous T-cell lymphoma, from its biology, subclassifications, targeted therapy, goals of treatment, novel toxicities, and so much more! Join Dr. Ken Miller as he delves into cutaneous T-cell lymphoma with two special guests; Dr. Francine Foss from Yale University School of Medicine and Dr. John Zic from Vanderbilt University Medical Center. Learn more about cutaneous T-cell lymphoma from a 60,000 foot view, disparities in the delivery of care, and exciting new research presented at the United States Cutaneous Lymphoma Consortium Annual Meeting. Tune in today!

A Deep Dive into Myelofibrosis Mar 23, 2022

Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center, Houston, TX Recorded on February 18, 2022 In this month’s episode, Dr. Srdan Verstovsek, from MD Anderson Cancer Center in Houston, Texas, joins us to discuss myelofibrosis. What is myelofibrosis? What is our understanding of the disease? What are the deciding factors for cells to branch off into myelofibrosis and not other myeloproliferative neoplasms? Tune in as we explore myelofibrosis, including discussion on diagnosing and staging, goals and considerations for therapy, the impact of COVID-19 on treatment, and new and emerging drugs in development. This podcast episode is supported by AbbVie Inc.

Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia: Part I Feb 17, 2022

Jacqueline C. Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY Recorded on February 1, 2022 Shared decision making between patients and their healthcare team is an important component to treatment, regardless of the diagnosis. For chronic leukemias, patient worries may be intensified when doctors suggest forgoing active treatment for a watch-and-wait approach. In this episode, Dr. Jacqueline Barrientos, from the Northwell Health Cancer Institute in Lake Success, New York, highlights the importance of shared decision making with her patients. Dr. Barrientos discusses challenges that arise, shared decision making across the multidisciplinary team, navigating second opinions, long-term and late effects, and maintaining open lines of communication. Listen in on this important conversation today! This podcast episode is supported by AbbVie Inc. and Genentech, Inc.

CAR T-cell Therapy in 2022: What You Need to Know Jan 25, 2022

Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on January 4, 2022 As we move into 2022, chimeric antigen receptor (CAR) T-cell therapy continues to be a very exciting and effective treatment option for some blood cancer patients. In this episode, Dr. Caron Jacobson, Assistant Professor of Medicine, Harvard Medical School, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute in Boston, MA, discusses updates in CAR T-cell therapy, including progress in managing toxicities, barriers to treatment, CAR T structure and manufacturing, other practical issues such as determining the best treatment option for patients facing serious disease, and future directions. Tune in to learn more! This podcast episode is supported by Bristol Myers Squibb, CRISPR Therapeutics, Inc., Kite, a Gilead Company and Novartis Pharmaceuticals Corporation.

Highpoints from Attending the 2021 American Society of Hematology Conference Jan 12, 2022

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 22, 2021 Each year, blood cancer professionals gather at the American Society of Hematology Annual Meeting to discuss the latest updates in blood cancer research, treatment, and clinical trials. In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, highlights the inflection points from the 63rd ASH Annual Meeting, including CAR T-cell therapy, bi-specific antibodies, and cell-free DNA. He reviews the latest data on Covid-19 and effectiveness of vaccinations in the blood cancer patient population. Tune in to this informative update today!

Updates on COVID-19 in Patients with Blood Cancer Dec 20, 2021

John P. Leonard, MD, Weill Cornell Medicine, New York Presbyterian, New York, NY Recorded on December 16, 2021 As 2021 comes to a close, the COVID-19 pandemic continues to evolve. In this episode, Dr. John Leonard, from Weill Cornell Medicine, New York Presbyterian Hospital, discusses the latest updates on how COVID-19 affects the blood cancer patient population. What is the value of the vaccine in blood cancer patients who are on treatment that diminishes immune response? What are the risks and benefits of an mRNA vaccine? What does treatment look like in both symptomatic and asymptomatic patients? How are we seeing the Omicron variant affecting this? Tune in to this important discussion today!

A Conversation on Adult Survivorship Nov 17, 2021

Maria Alma Rodriguez, MD, MACP, CMQ, The University of Texas MD Anderson Cancer Center, Houston, TX Recorded on October 21, 2021 In this episode, Dr. Maria Alma Rodriguez from The University of Texas MD Anderson Cancer Center, joins us in discussing the long-term and late effects of cancer treatment, including strategies to support survivors with physical and psychosocial effects. Dr. Rodriguez describes barriers to follow-up care, including why some patients may be lost to this process, challenges to following a cancer survivorship plan, the importance of follow-up care coordination, and how the COVID-19 pandemic has impacted survivorship care. Join us today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Pharmacyclics LLC, An AbbVie Company & Janssen Biotech, Inc.

The Advanced Practice Provider’s Role in Treating Newly Diagnosed Patients with Myeloma Oct 19, 2021

Daniel Verina, DNP, ACNP-BC, Mount Sinai Medical Center, New York, NY Recorded on October 1, 2021 Advanced practice providers, nurses, and other members of the multidisciplinary healthcare team play an important role in treating and supporting newly diagnosed myeloma patients. In this month’s episode, Daniel Verina, DNP, ACNP-BC, Acute Care Nurse Practitioner, Multiple Myeloma Program, at the Mount Sinai Medical Center in New York, shares his perspective into treating newly diagnosed myeloma patients, including how to navigate questions about embarking on the treatment journey, potential side effects, and survival rates. He shares his thoughts on how to best support both the patient and caregiver, navigating discussion surrounding clinical trials, and what challenges lie ahead. Tune in today! This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.

The Physician’s Role in Treating Newly Diagnosed Patients with Myeloma Oct 11, 2021

Joshua Richter, MD, Icahn School of Medicine at Mount Sinai, New York, NY Recorded on September 10, 2021 Treating myeloma patients, especially newly diagnosed, can be very complex. How are treatment decisions determined? Who is eligible to receive a transplant? What is the patient’s role in making treatment decisions? In this month’s episode, Dr. Joshua Richter from the Icahn School of Medicine at Mount Sinai Hospital in New York, provides his perspective on treating newly diagnosed myeloma patients, including smoldering myeloma, describes the evolution of CRAB criteria to SLIM CRAB criteria, discusses the importance of quality-of-life considerations, describes how COVID-19 has affected treatment, and reviews exciting myeloma treatment options on the horizon. This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.

Clinical Trials: A Healthcare Professional’s Perspective Sep 30, 2021

Lorenzo Falchi, MD and Leah Szumita, MS, RN, CCRN, ACNS-BC Recorded on August 5, 2021 Clinical trials are the foundation of advancing treatment options. Understanding their importance, dispelling myths and fears about enrollment, and acknowledging disparities in access can help providers educate their patients and discuss treatment in a clinical trial as an option at any point in the patient’s cancer journey. In this episode, we welcome special guest host Leah Szumita, MS, RN, CCRN, ACNS-BC, Director of The Leukemia & Lymphoma Society’s Clinical Trial Support Center as she speaks with Lorenzo Falchi, MD, Assistant Attending, Lymphoma Service, Memorial Sloan-Kettering Cancer Center in New York City, about the importance of clinical trials, understanding patient concerns, barriers to participation and strategies to overcome these barriers, and how clinical trials have been impacted by COVID-19.

Wearing Two Hats: Supporting the Childhood Cancer Patient as Nurse & Parent Sep 01, 2021

David Tate, BSN, RN, PHN, Rio Bravo-Greeley School, Bakersfield, CA Recorded on August 11, 2021 September is Childhood Cancer Awareness Month, a time to recognize the children and families affected by blood cancer. In this month’s special episode, we are joined by David Tate, a registered nurse in the Rio Bravo-Greeley School system in Bakersfield, California to discuss his journey from the father of a cancer survivor to healthcare professional. David shares with us the story of his son’s diagnosis with leukemia at seven months old, how that journey influenced his career in nursing, and how he leans on his experience to help other families navigating this path. Tune in to this heartfelt episode today!

Addressing Healthcare Disparities in Cancer Care Aug 18, 2021

Justine M. Kahn, MD, MS, Columbia University Irving Medical Center, New York, NY Recorded on July 13, 2021 Healthcare disparities are a known factor in cancer care. Understanding these disparities can enable healthcare professionals to more effectively communicate with and treat their patients. In this episode, Dr. Justine Kahn, from the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center in New York City, defines and describes existing healthcare disparities, addresses ways to eliminate disparities, including removing barriers and increasing access to care, underscores the impact of insurance, and discusses the importance of enhancing awareness among primary care providers to reduce challenges that lead to delayed diagnoses. Tune into this important episode for more tips on how providers can eliminate disparities in their practice!

T-cell Lymphoma: A Discussion on Treatment and Patient Support Jul 19, 2021

Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on June 18, 2021 Tune in to this very informative and interesting conversation on T-cell lymphoma! Dr. Steven Horwitz, from Memorial Sloan Kettering Cancer Center in New York City, discusses types and diagnostic tests used to identify T-cell lymphoma, goals of treatment, approved and emerging treatment options, including immunotherapy and clinical trials, strategies to manage side effects, including when to stop therapy, and the importance of the multidisciplinary healthcare team.

A Discussion on MRD: Practical Information for Providers Jun 22, 2021

Jeffrey L. Wolf, MD, University of California San Francisco, San Francisco, CA Recorded on May 27, 2021 In this episode, Dr. Jeffrey Wolf, from the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, explains what measurable residual disease (MRD) is, how providers can explain the role of MRD to patients, including understanding the tests used, how to counsel patients when there is MRD, where testing is done for patients treated in the community, the way MRD test results will be used in the future, and so much more. Tune in today as Dr. Wolf explores MRD with our moderator, Dr. Ken Miller! This podcast episode is supported by Amgen.

A Deeper Dive into Cancer Genomics May 26, 2021

Justin M. Watts, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL Recorded on May 14, 2021 Terminology, available tests, the impact of epigenetics, and the significance of mutations. Understanding the role of genomics in cancer care can be complex. Tune in as Dr. Justin Watts from the Sylvester Comprehensive Cancer Center in Miami, breaks down cancer genomics, discusses the implications of treatment, outlines the various tests available, including their strengths and weaknesses, the importance of educating patients on the meaning of these tests, and the future of genomic testing in hematologic malignancies.

The Pharmacist’s Role on the Blood Cancer Treatment Team May 06, 2021

Peter Campbell, PharmD, BCOP, Columbia University Irving Medical Center, New York, NY Recorded on April 23, 2021 The interprofessional oncology team is comprised of many healthcare professionals, each playing an important role in contributing to a patient’s care. Join Dr. Peter Campbell, Clinical Pharmacy Manager from Columbia University Irving Medical Center, as he discusses the vital role of pharmacists on the multidisciplinary team. Dr. Campbell discusses challenges with access to treatment, cost of drugs, and adherence. He reviews many common and novel side effects patients experience, understanding drug-drug interactions, how to determine when to stop treatment, and how to navigate drug shortages. Join this interesting conversation to learn more about exciting drugs coming down the pipeline, how COVID-19 has impacted treatment, and so much more!

A Conversation on Multiple Myeloma with Edward Stadtmauer, MD Mar 23, 2021

Edward A. Stadtmauer, MD, The University of Pennsylvania, Philadelphia, PA Recorded on February 23, 2021 In recognition of March being Myeloma Awareness Month, The Leukemia & Lymphoma Society is pleased to share this informative podcast episode on updates and advancements in multiple myeloma. Healthcare professionals are challenged to stay up-to-date on new and emerging treatments options, including updates in immunotherapy, and to incorporate these treatment approaches into decision making. Dr. Edward Stadtmauer, from The University of Pennsylvania, shares his insights into these topics, as well as discusses myeloma in underserved communities, treatment in the time of the COVID-19 pandemic, and exciting advances in multiple myeloma.

The COVID-19 Vaccine and Your Patient with Cancer Mar 10, 2021

Michael Angarone, DO, FIDSA, Feinberg School of Medicine, Chicago, IL Recorded on February 25, 2021 There are so many questions cancer patients and their families have about the COVID-19 vaccine. What are the differences between the vaccines available? How do they work? Who should get vaccinated? Can one resume activities once vaccinated? This important podcast episodes aims to dispel myths surrounding the COVD-19 vaccine and reiterate its safety for oncology patients, their families, and healthcare professionals. Join our guest, Dr. Michael Angarone of Northwestern University, as he underscores the importance of this vaccine.

Managing Treatment for Patients with Relapsed/Refractory Lymphoma Feb 24, 2021

Sonali M. Smith, MD, FASCO, The University of Chicago, Chicago, IL Recorded on January 25, 2021 How do we start the conversation? How do we discuss patient expectation and the likelihood of relapse? What role does the timing of relapse play? In this episode, Dr. Sonali Smith, the Elwood V. Jensen Professor of Medicine at The University of Chicago, discusses expectations for disease control and for relapse, the mechanisms of resistance, exciting advances in the treatment of relapsed/refractory lymphoma, including new treatments, and so much more. Tune in to this important talk today! This podcast episode is supported by Epizyme.

What’s New in Treatment for Acute Myeloid Leukemia (AML) Feb 03, 2021

Olatoyosi Odenike, MD and Wendy Stock, MD Recorded on January 15, 2021 Join Drs. Wendy Stock and Olatoyosi Odenike from The University of Chicago Medicine, in an important discussion on the progress in the treatment of acute myeloid leukemia, including important updates from the LLS Beat AML Master Trial. Drs. Stock and Odenike talk with Dr. Ken Miller about determining a treatment plan for each patient, the role genetics and epigenetics may play, what the ultimate goals of care are, including having difficult conversations with patients regarding treatment, and monitoring for measurable residual disease and maintenance therapy. Be a part of the conversation today!

Progress in the Treatment of Follicular Lymphoma Jan 20, 2021

Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR Recorded on December 14, 2020 This podcast episode is supported by Epizyme.

Current Applications of Cancer Genomics: Focus on CLL Dec 15, 2020

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA Recorded on November 19, 2020 This podcast episode is supported by Foundation Medicine, Inc.

Supporting LGBTQI Cancer Patients Nov 17, 2020

Matthew B. Schabath, PhD, Moffitt Cancer Center, Tampa, FL Recorded on November 2, 2020

A Deeper Dive into MRD: A Conversation with Gail Roboz, MD Oct 19, 2020

Gail J. Roboz, MD, Weill Cornell Medical College, New York, NY Recorded on October 2, 2020 This podcast episode is supported by Amgen.

Communicating with Caregivers: Strategies for HCPs Sep 22, 2020

Allison J. Applebaum, Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY Recorded on June 26, 2020

Communicating with the Young Adult with Blood Cancer Sep 03, 2020

Carma Bylund, PhD, FACH, and Carla Fisher, PhD Recorded on August 13, 2020

Facilitating the Learning Experience of Children and AYAs During and After Cancer Treatment Aug 10, 2020

Nicole Gutman, MS, and Mary Kay Irwin, EdD Recorded on May 19, 2020

Myelodysplastic Syndromes (MDS): Caring for Low and High-Risk Patients Jul 22, 2020

James M. Foran, MD, FRCPC, Mayo Clinic Cancer Center, Jacksonville, FL Recorded on May 28, 2020

Treating Children with Cancer during the COVID-19 Pandemic Jun 17, 2020

Jennifer Levine, MD, and Maria Luisa Sulis, MD, MS Recorded on June 5, 2020

CML: Treatment Considerations and Survivorship Challenges Jun 02, 2020

Alison Loren, MD, MSCE, Raymond and Ruth Perelman School of Medicine, Philadelphia, PA Recorded on April 21, 2020

Understanding the Complexities of Myeloproliferative Neoplasms May 21, 2020

Raajit K. Rampal, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY Recorded on March 24, 2020

COVID-19: What Healthcare Professionals Need to Know Apr 20, 2020

Tobias M. Hohl, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY Recorded on April 15, 2020

The Role of the PA and Nurse in Treating Patients during the COVID-19 Pandemic Apr 14, 2020

Kerry Cook, PA-C, New York Presbyterian/Columbia University Irving Medical Center, New York, NY Recorded on April 8, 2020

Insights in to Transplantation with Dr. Fredrick Appelbaum Apr 14, 2020

Frederick R. Appelbaum, MD, Fred Hutchinson Cancer Research Center, Seattle, WA Recorded on February 4, 2020

Disparities in Cancer Care: Focus on Myeloma Mar 24, 2020

Edith P. Mitchell, MD, MACP, FCPP, Sydney Kimmel Cancer Center at Jefferson, Philadelphia, PA Recorded on January 15, 2020

Long-Term and Late Effects of Childhood Cancer: A Conversation on Survivorship Feb 25, 2020

Jacqueline Casillas, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA Recorded on January 8, 2020

Compassion Fatigue in Cancer Care Jan 23, 2020

Marybeth Medicke, MSN, RN, El Paso Community College, El Paso, TX Recorded on November 21, 2019

Mantle Cell Lymphoma: Disease and Treatment Updates Dec 17, 2019

Anita Kumar, MD, Memorial Sloan Kettering Cancer Center, Basking Ridge, NJ Recorded on November 11, 2019

Treatment Considerations for NHL as a Chronic Disease Nov 19, 2019

Susan McCall, MSN, ANP-BC, AOCNP®, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on September 18, 2019

CAR T-cell Therapy: The Nurse’s Role in Treating Patients Oct 22, 2019

Elizabeth A. Weber, BSN, RN, Heather DiFilippo, MSN, CRNP and Erin Medoff, RN, MSN, APRN Recorded live at The Leukemia & Lymphoma Society’s Symposium on CAR T-cell Therapy on June 28, 2019

A Discussion on the Future of CAR T-cell Therapy with Dr. Frederick Locke Sep 24, 2019

Frederick L. Locke, MD, Moffitt Cancer Center, Tampa, FL Recorded on September 3, 2019 This podcast episode is supported by Allogene Therapeutics, Inc.

CAR T-cell Therapy: A Deeper Dive into Adverse Effects and Financial Toxicities Sep 05, 2019

Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center and Gunjan Shah, MD, Memorial Sloan Kettering Cancer Center Recorded live at The Leukemia & Lymphoma Society’s Symposium on CAR T-cell Therapy on June 28, 2019

CAR T-cell Therapy: A 60,000 Foot View Aug 22, 2019

Dennis Cooper, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ Recorded live at The Leukemia & Lymphoma Society’s Symposium on CAR T-cell Therapy on June 28, 2019

Caring for the patient with CLL with Susan O’Brien, MD Jul 23, 2019

Susan O’Brien, MD, University of California, Irvine, CA Recorded on April 5, 2019

An Overview of the Beat AML® Master Trial: Pioneering Treatment Options and Patient Services Jun 26, 2019

Amy Burd, PhD, Vice President of Research and Strategy, and Alissa Gentile, MSN, RN, Director of the Clinical Trial Support Center at The Leukemia & Lymphoma Society Recorded on May 10, 2019

Unique Challenges for Young Adult Cancer Survivors: What You Should Know May 20, 2019

Brad Zebrack, PhD, MSW, The University of Michigan School of Social Work, Ann Arbor, MI Recorded on March 5, 2019

Hearing the Patient’s Voice: A Discussion on Myelodysplastic Syndrome with a Survivor, a Caregiver, and a Physician Apr 16, 2019

Richard, MDS survivor since 2016, Nancy, Caregiver, and Vu Duong, MD, University of Maryland School of Medicine, Baltimore, MD Recorded on February 26, 2019

A Conversation on AL Amyloidosis with Dr. Raymond Comenzo, MD Mar 26, 2019

Raymond Comenzo, MD, Tufts Medical Center, Boston, MA Recorded on December 14, 2018

Childhood Blood Cancers: Focus on Acute Lymphoblastic Leukemia with Dr. Lewis Silverman, MD Feb 25, 2019

Lewis Silverman, MD, Boston Children’s Hospital, Boston, MA Recorded on February 7, 2019

Part II of Understanding Multiple Myeloma Jan 18, 2019

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on December 28, 2018

Part I of Understanding Multiple Myeloma Jan 18, 2019

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on December 28, 2018

A Conversation on AML: Diagnosis and Treatment Jan 18, 2019

Alice Mims, MD, MSCR, The James, The Ohio State University Comprehensive Cancer Center, Columbus, OH Recorded on January 10, 2019

BPDCN – Expert Insight Into a Rare Blood Cancer Jan 02, 2019

Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX Recorded on December 11, 2018

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected